SI2089367T1 - Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev - Google Patents

Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev

Info

Publication number: SI2089367T1
Authority: SI; Slovenia
Prior art keywords: receptor antagonists; mineralocorticoid receptor; pyrazoline compounds; pyrazoline; compounds
Prior art date: 2006-10-31

Application number

SI200730830T

Other languages

English (en)

Inventor

Marvin Jay Meyers

Graciela Barbieri Arhancet

Xiangyang Chen

Susan Landis Hockerman

Scott Allen Long

Matthew William Mahoney

David Bruce Reitz

Joseph Gerace Rico

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-31

Filing date

2007-10-17

Publication date

2012-02-29

2007-10-17 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2012-02-29 Publication of SI2089367T1 publication Critical patent/SI2089367T1/sl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

SI200730830T 2006-10-31 2007-10-17 Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev SI2089367T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US86360606P	2006-10-31	2006-10-31
PCT/IB2007/003207 WO2008053300A1 (en)	2006-10-31	2007-10-17	Pyrazoline compounds as mineralocorticoid receptor antagonists
EP07825488A EP2089367B1 (en)	2006-10-31	2007-10-17	Pyrazoline compounds as mineralocorticoid receptor antagonists

Publications (1)

Publication Number	Publication Date
SI2089367T1 true SI2089367T1 (sl)	2012-02-29

Family

ID=39027523

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200730830T SI2089367T1 (sl)	2006-10-31	2007-10-17	Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev

Country Status (40)

Country	Link
US (3)	US7781428B2 (sl)
EP (1)	EP2089367B1 (sl)
JP (1)	JP4977760B2 (sl)
KR (1)	KR101107800B1 (sl)
CN (1)	CN101541757A (sl)
AP (1)	AP2527A (sl)
AR (1)	AR063529A1 (sl)
AT (1)	ATE537151T1 (sl)
AU (1)	AU2007315884B2 (sl)
BR (1)	BRPI0717937A2 (sl)
CA (1)	CA2667966C (sl)
CL (1)	CL2007003154A1 (sl)
CO (1)	CO6160307A2 (sl)
CR (1)	CR10725A (sl)
CU (1)	CU23779B7 (sl)
CY (1)	CY1112311T1 (sl)
DK (1)	DK2089367T3 (sl)
EA (1)	EA016370B1 (sl)
ES (1)	ES2375877T3 (sl)
GE (1)	GEP20115239B (sl)
GT (1)	GT200700096A (sl)
HN (1)	HN2007000437A (sl)
HR (1)	HRP20120078T1 (sl)
IL (1)	IL198241A0 (sl)
MA (1)	MA30821B1 (sl)
MX (1)	MX2009004662A (sl)
MY (1)	MY145795A (sl)
NI (1)	NI200900071A (sl)
NO (1)	NO20091741L (sl)
NZ (1)	NZ575923A (sl)
PE (1)	PE20081472A1 (sl)
PL (1)	PL2089367T3 (sl)
PT (1)	PT2089367E (sl)
RS (2)	RS52203B (sl)
SI (1)	SI2089367T1 (sl)
TN (1)	TN2009000160A1 (sl)
TW (1)	TWI357327B (sl)
UA (1)	UA92670C2 (sl)
UY (1)	UY30670A1 (sl)
WO (1)	WO2008053300A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20091057A1 (es)	2007-12-19	2009-07-20	Lilly Co Eli	Antagonistas del receptor mineralcorticoide y metodos de uso
WO2011059784A1 (en) *	2009-10-29	2011-05-19	Bristol-Myers Squibb Company	Tricyclic heterocyclic compounds
ES2566934T3 (es)	2010-05-10	2016-04-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
CA2798831A1 (en)	2010-05-11	2011-11-17	Pfizer Inc.	Morpholine compounds as mineralocorticoid receptor antagonists
EP2582365B1 (en)	2010-06-16	2019-03-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions for stimulating reepithelialisation during wound healing
CN102372710A (zh) *	2010-08-18	2012-03-14	山东轩竹医药科技有限公司	作为盐皮质激素受体拮抗剂的并环类化合物
US10172907B2 (en)	2010-10-05	2019-01-08	Nova Southeastern University	Compositions comprising β-arrestin 1 and methods of use thereof for therapeutic modulation of aldosterone levels in heart disease
RS58274B1 (sr)	2014-06-30	2019-03-29	Astrazeneca Ab	Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora
JP6835836B2 (ja)	2015-10-13	2021-02-24	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	脈絡膜血管新生の処置のための方法及び医薬組成物
US20190262363A1 (en)	2016-07-26	2019-08-29	INSERM (Institut National de la Santé et de la Recherche Médicale	Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
WO2018045149A1 (en)	2016-09-02	2018-03-08	Bristol-Myers Squibb Company	Substituted tricyclic heterocyclic compounds
US11059784B2 (en)	2017-08-09	2021-07-13	Bristol-Myers Squibb Company	Oxime ether compounds
WO2019032632A1 (en)	2017-08-09	2019-02-14	Bristol-Myers Squibb Company	ALKYLPHENYL COMPOUNDS
CN109051490A (zh)	2018-09-18	2018-12-21	深圳市鲸仓科技有限公司	可移动式密集存拣装置
EP4118235A1 (en)	2020-03-11	2023-01-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en)	2021-08-31	2023-03-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of ocular rosacea
CN113679716B (zh)	2021-10-13	2024-03-26	史大永	溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
CN114230457B (zh) *	2022-01-04	2023-06-09	中山大学	一类2-亚苄基四氢萘酮衍生物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1086068A (en) *	1964-09-02	1967-10-04	Ici Ltd	Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein
BE789948A (fr) *	1971-10-13	1973-04-11	Sandoz Sa	Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816438A (en) *	1972-12-22	1974-06-11	Sandoz Ag	2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843666A (en) *	1973-05-29	1974-10-22	Sandoz Ag	Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US4866025A (en) *	1988-09-30	1989-09-12	Eastman Kodak Company	Thermally-transferable fluorescent diphenylpyrazolines
ES2098547T3 (es) *	1992-01-23	1997-05-01	Pfizer	Benzopirano y otros antagonistas de ltb4 relacionados.
GB9318691D0 (en)	1993-09-09	1993-10-27	Merck Sharp & Dohme	Therapeutic agents
ID16283A (id)	1996-03-20	1997-09-18	Astra Pharma Prod	Senyawa yang berguna dibidang farmasi
JP2001501180A (ja) *	1996-09-05	2001-01-30	アストラ・フアーマシユウテイカルズ・リミテツド	新規なアリールピリダジン
JPH10273467A (ja) *	1997-01-29	1998-10-13	Snow Brand Milk Prod Co Ltd	新規テトラロン又はベンゾピラノン誘導体及びその製造方法
IT1292092B1 (it)	1997-06-05	1999-01-25	Geange Ltd	Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
WO1999055335A1 (en)	1998-04-30	1999-11-04	Basf Aktiengesellschaft	Substituted tricyclic pyrazole derivatives with protein kinase activity
US6432974B1 (en) *	2000-02-04	2002-08-13	Wyeth	Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
AU2003249597B2 (en)	2002-03-08	2007-06-28	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors
WO2003078394A1 (en)	2002-03-15	2003-09-25	Eli Lilly And Company	Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
TW200400816A (en)	2002-06-26	2004-01-16	Lilly Co Eli	Tricyclic steroid hormone nuclear receptor modulators
BR0313176A (pt)	2002-08-02	2005-06-14	Vertex Pharma	Composições de pirazol úteis como inibidores de gsk-3
CN1681501A (zh)	2002-09-18	2005-10-12	辉瑞产品公司	作为转化生长因子(tgf)抑制剂的吡唑衍生物
EP1597254A1 (en)	2003-01-22	2005-11-23	Eli Lilly and Company	Indole-derivative modulators of steroid hormone nuclear receptors
DE602004014640D1 (de) *	2003-12-19	2008-08-07	Lilly Co Eli	Tricyclische modulatoren von nuklearen steroidhormonrezeptoren
JP2007230869A (ja)	2004-04-05	2007-09-13	Takeda Chem Ind Ltd	アルドステロン受容体拮抗剤
WO2006010142A2 (en)	2004-07-14	2006-01-26	Ligand Pharmaceuticals, Inc.	Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
WO2006012642A2 (en)	2004-07-30	2006-02-02	Exelixis, Inc.	Pyrrole derivatives as pharmaceutical agents
CA2593156C (en)	2005-01-10	2015-05-05	Exelixis, Inc.	Heterocyclic carboxamide compounds as steroid nuclear receptors ligands
JPWO2006077821A1 (ja)	2005-01-19	2008-06-19	大日本住友製薬株式会社	アルドステロン受容体調節剤としての芳香族スルホン化合物
WO2006086358A2 (en)	2005-02-10	2006-08-17	Merck & Co., Inc.	Mitotic kinesin inhibitors

2007
- 2007-10-17 MX MX2009004662A patent/MX2009004662A/es active IP Right Grant
- 2007-10-17 ES ES07825488T patent/ES2375877T3/es active Active
- 2007-10-17 EP EP07825488A patent/EP2089367B1/en active Active
- 2007-10-17 SI SI200730830T patent/SI2089367T1/sl unknown
- 2007-10-17 MY MYPI20091613A patent/MY145795A/en unknown
- 2007-10-17 NZ NZ575923A patent/NZ575923A/en not_active IP Right Cessation
- 2007-10-17 GE GEAP200711240A patent/GEP20115239B/en unknown
- 2007-10-17 AT AT07825488T patent/ATE537151T1/de active
- 2007-10-17 PL PL07825488T patent/PL2089367T3/pl unknown
- 2007-10-17 BR BRPI0717937-5A2A patent/BRPI0717937A2/pt not_active IP Right Cessation
- 2007-10-17 DK DK07825488.5T patent/DK2089367T3/da active
- 2007-10-17 KR KR1020097008836A patent/KR101107800B1/ko not_active IP Right Cessation
- 2007-10-17 AU AU2007315884A patent/AU2007315884B2/en not_active Ceased
- 2007-10-17 CN CNA2007800433330A patent/CN101541757A/zh active Pending
- 2007-10-17 WO PCT/IB2007/003207 patent/WO2008053300A1/en active Application Filing
- 2007-10-17 CA CA2667966A patent/CA2667966C/en not_active Expired - Fee Related
- 2007-10-17 RS RS20120051A patent/RS52203B/en unknown
- 2007-10-17 AP AP2009004822A patent/AP2527A/xx active
- 2007-10-17 PT PT07825488T patent/PT2089367E/pt unknown
- 2007-10-17 RS RSP-2009/0208A patent/RS20090208A/sr unknown
- 2007-10-17 JP JP2009533977A patent/JP4977760B2/ja not_active Expired - Fee Related
- 2007-10-17 UA UAA200903302A patent/UA92670C2/ru unknown
- 2007-10-17 EA EA200970341A patent/EA016370B1/ru not_active IP Right Cessation
- 2007-10-24 US US11/923,248 patent/US7781428B2/en not_active Expired - Fee Related
- 2007-10-29 UY UY30670A patent/UY30670A1/es not_active Application Discontinuation
- 2007-10-29 AR ARP070104787A patent/AR063529A1/es not_active Application Discontinuation
- 2007-10-30 GT GT200700096A patent/GT200700096A/es unknown
- 2007-10-30 TW TW096140838A patent/TWI357327B/zh not_active IP Right Cessation
- 2007-10-30 PE PE2007001482A patent/PE20081472A1/es not_active Application Discontinuation
- 2007-10-31 CL CL200703154A patent/CL2007003154A1/es unknown
- 2007-10-31 HN HN2007000437A patent/HN2007000437A/es unknown
2009
- 2009-04-17 CR CR10725A patent/CR10725A/es not_active Application Discontinuation
- 2009-04-17 CU CU20090058A patent/CU23779B7/es not_active IP Right Cessation
- 2009-04-20 IL IL198241A patent/IL198241A0/en unknown
- 2009-04-21 CO CO09040130A patent/CO6160307A2/es unknown
- 2009-04-24 TN TNP2009000160A patent/TN2009000160A1/fr unknown
- 2009-04-29 NI NI200900071A patent/NI200900071A/es unknown
- 2009-04-30 MA MA31831A patent/MA30821B1/fr unknown
- 2009-05-04 NO NO20091741A patent/NO20091741L/no not_active Application Discontinuation
2010
- 2010-07-12 US US12/834,117 patent/US20100280016A1/en not_active Abandoned
2011
- 2011-10-20 US US13/277,270 patent/US20120035131A1/en not_active Abandoned
2012
- 2012-01-23 HR HR20120078T patent/HRP20120078T1/hr unknown
- 2012-01-23 CY CY20121100076T patent/CY1112311T1/el unknown

Also Published As

Publication number	Publication date
GEP20115239B (en)	2011-06-10
UA92670C2 (ru)	2010-11-25
GT200700096A (es)	2010-07-15
CL2007003154A1 (es)	2008-05-09
MY145795A (en)	2012-04-30
US7781428B2 (en)	2010-08-24
WO2008053300A1 (en)	2008-05-08
US20080167294A1 (en)	2008-07-10
AU2007315884A1 (en)	2008-05-08
CY1112311T1 (el)	2015-12-09
PL2089367T3 (pl)	2012-04-30
UY30670A1 (es)	2008-05-31
NZ575923A (en)	2011-01-28
NO20091741L (no)	2009-05-29
MA30821B1 (fr)	2009-10-01
RS20090208A (en)	2010-06-30
US20120035131A1 (en)	2012-02-09
CR10725A (es)	2009-05-12
RS52203B (en)	2012-10-31
HRP20120078T1 (hr)	2012-02-29
JP2010508257A (ja)	2010-03-18
AP2009004822A0 (en)	2009-04-30
EP2089367B1 (en)	2011-12-14
EA200970341A1 (ru)	2009-10-30
CN101541757A (zh)	2009-09-23
DK2089367T3 (da)	2012-02-06
EA016370B1 (ru)	2012-04-30
BRPI0717937A2 (pt)	2013-12-03
JP4977760B2 (ja)	2012-07-18
KR101107800B1 (ko)	2012-01-25
CA2667966C (en)	2011-08-02
NI200900071A (es)	2010-03-08
CU20090058A7 (es)	2011-07-11
CU23779B7 (es)	2012-02-15
TW200822924A (en)	2008-06-01
CA2667966A1 (en)	2008-05-08
US20100280016A1 (en)	2010-11-04
AP2527A (en)	2012-12-06
EP2089367A1 (en)	2009-08-19
PT2089367E (pt)	2012-02-01
KR20090060371A (ko)	2009-06-11
TN2009000160A1 (fr)	2010-10-18
IL198241A0 (en)	2009-12-24
PE20081472A1 (es)	2008-10-18
ATE537151T1 (de)	2011-12-15
HN2007000437A (es)	2011-01-17
ES2375877T3 (es)	2012-03-07
CO6160307A2 (es)	2010-05-20
TWI357327B (en)	2012-02-01
AR063529A1 (es)	2009-01-28
AU2007315884B2 (en)	2012-10-04
MX2009004662A (es)	2009-05-22

Publication	Publication Date	Title
IL198241A0 (en)	2009-12-24	Pyrazoline compounds as mineralocorticoid receptor antagonists
HK1244694A1 (zh)	2018-08-17	新穎的胰高血糖素受體拮抗劑
HRP20151108T1 (en)	2015-11-20	Nogo receptor antagonists
IL198825A0 (en)	2010-02-17	Substituted diazepan compounds as orexin receptor antagonists
EP2058304A4 (en)	2012-10-10	P2X4 RECEPTOR ANTAGONIST
EP2099454A4 (en)	2010-11-10	AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
ZA201001597B (en)	2012-09-29	Octahydropentalene compounds as chemokine receptor antagonists
HK1147674A1 (en)	2011-08-19	Heterocyclic compounds as crth2 receptor antagonists crth2
EP2184278A4 (en)	2011-08-03	P2X4 RECEIVER ANTAGONIST
IL196587A0 (en)	2009-11-18	2-phenyl-indoles as prostaglandin d2 receptor antagonists
HK1136302A1 (en)	2010-06-25	Progesterone receptor antagonists
IL184816A0 (en)	2007-12-03	2-phenyl-indoles as prostaglandin d2 receptor antagonists
ZA200903334B (en)	2010-04-28	Substituted diazepan compounds as orexin receptor antagonists
HK1163063A1 (en)	2012-09-07	Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity 5-ht2b -3-
IL198542A0 (en)	2010-02-17	2-aminoquinolines as 5-ht(5a)receptor antagonists
ZA200808766B (en)	2010-01-27	Nitrated heterocyclic compounds as endothelin receptor antagonist
IL205949A0 (en)	2010-11-30	3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
EP2120564A4 (en)	2011-05-04	BENZAZEPINE COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS
ZA200904479B (en)	2010-09-29	Nitroderivatives as angiotensin II receptor antagonists
ZA200903499B (en)	2010-03-31	Indoles which act as via receptor antagonists
ZA200802339B (en)	2009-10-28	Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
IL207438A0 (en)	2010-12-30	2-aminoquinolines as 5-ht5a receptor antagonists
ZA200810564B (en)	2009-11-25	2-phenyl-indoles as prostaglandin D2 receptor antagonists
GB0701632D0 (en)	2007-03-07	MET receptor antagonists